US5833975A
(en)
*
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
US5174993A
(en)
*
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
US7767449B1
(en)
|
1981-12-24 |
2010-08-03 |
Health Research Incorporated |
Methods using modified vaccinia virus
|
CA1340203C
(en)
*
|
1987-09-16 |
1998-12-15 |
Noboru Yanagida |
Recombinant apivoxvirus
|
DE4090351T1
(de)
*
|
1989-03-08 |
1997-07-24 |
Health Research Inc |
Rekombinantes Pockenvirus-Wirtsselektionssystem
|
US5766597A
(en)
*
|
1991-03-07 |
1998-06-16 |
Virogenetics Corporation |
Malaria recombinant poxviruses
|
US5766598A
(en)
*
|
1991-03-07 |
1998-06-16 |
Virogenetics Corporation |
Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
|
CA2106464A1
(en)
*
|
1991-03-20 |
1992-09-21 |
Enzo Paoletti |
Malaria recombinant poxvirus vaccine
|
AU5543294A
(en)
*
|
1993-10-29 |
1995-05-22 |
Pharmos Corp. |
Submicron emulsions as vaccine adjuvants
|
US5961970A
(en)
*
|
1993-10-29 |
1999-10-05 |
Pharmos Corporation |
Submicron emulsions as vaccine adjuvants
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
EP0753581A1
(de)
*
|
1995-07-10 |
1997-01-15 |
Immuno Ag |
Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe
|
EP0951555A2
(de)
*
|
1996-09-24 |
1999-10-27 |
Bavarian Nordic Research Institute A/S |
Rekombinantes mva-virus das dengue-virus antigene exprimiert und dessen verwendung in impfstoffen
|
GB9711957D0
(en)
|
1997-06-09 |
1997-08-06 |
Isis Innovation |
Methods and reagents for vaccination
|
US20030138454A1
(en)
*
|
1997-06-09 |
2003-07-24 |
Oxxon Pharmaccines, Ltd. |
Vaccination method
|
US6572874B1
(en)
|
1998-05-15 |
2003-06-03 |
Umd, Inc. |
Vaginal delivery of bisphosphonates
|
US6197327B1
(en)
*
|
1997-06-11 |
2001-03-06 |
Umd, Inc. |
Device and method for treatment of dysmenorrhea
|
US6416779B1
(en)
|
1997-06-11 |
2002-07-09 |
Umd, Inc. |
Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
US6582693B2
(en)
*
|
1998-11-30 |
2003-06-24 |
Lemery, S.A. De C.V. |
Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
|
US20040265324A1
(en)
*
|
1999-03-23 |
2004-12-30 |
Cardosa Mary Jane |
Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
|
WO2000073476A1
(en)
*
|
1999-05-28 |
2000-12-07 |
Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh |
Vector for integration of heterologous sequences into poxviral genomes
|
US6497883B1
(en)
|
1999-06-10 |
2002-12-24 |
Merial |
Porcine circovirus recombinant poxvirus vaccine
|
US8017590B1
(en)
|
1999-10-22 |
2011-09-13 |
Sanofi Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
EP2388015A1
(de)
|
2000-03-02 |
2011-11-23 |
Emory University |
DNA-Expressionsvektoren und Verwendungsverfahren
|
US20040105871A1
(en)
*
|
2000-03-02 |
2004-06-03 |
Robinson Harriet L. |
Compositions and methods for generating an immune response
|
US8623379B2
(en)
*
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
CA2397675C
(en)
*
|
2000-03-14 |
2012-11-13 |
Anton Mayr |
Altered strain of the modified vaccinia virus ankara (mva)
|
EP1282702B1
(de)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
DE10042598A1
(de)
*
|
2000-08-30 |
2002-03-28 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
|
US7445924B2
(en)
*
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
CZ295808B6
(cs)
|
2000-11-23 |
2005-11-16 |
Bavarian Nordic A/S |
Modifikovaný virus vakcinie typu Ankara
|
CN1176945C
(zh)
*
|
2001-02-01 |
2004-11-24 |
中国人民解放军第二军医大学 |
疟原虫融合抗原及其制法和用途
|
ATE445411T1
(de)
*
|
2001-03-08 |
2009-10-15 |
Us Gov Health & Human Serv |
Mva-exprimierende modifizierte hiv-envelope-, gag-und pol-gene
|
UA82466C2
(uk)
*
|
2001-07-18 |
2008-04-25 |
Бавариан Нордика А/С |
Спосіб посилення ампліфікації хордопоксвірусу
|
GB0118532D0
(en)
*
|
2001-07-30 |
2001-09-19 |
Isis Innovation |
Materials and methods relating to improved vaccination strategies
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
EP2172552A3
(de)
|
2001-10-11 |
2010-07-21 |
Merck Sharp & Dohme Corp. |
Rekombinante Nukleinsäuren beinhaltend Regionen von AD6
|
AU2002347317B2
(en)
|
2001-11-30 |
2008-06-26 |
Isis Innovation Limited |
Vaccine
|
HUP0402179A3
(en)
*
|
2001-12-10 |
2012-09-28 |
Bavarian Nordic As |
Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
|
US8921534B2
(en)
*
|
2001-12-12 |
2014-12-30 |
Sanofi Pasteur Limited |
Enhancement of the immune response using CD36-binding domain
|
US7501127B2
(en)
|
2002-05-16 |
2009-03-10 |
Bavarian Nordic A/S |
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
|
BRPI0313559B8
(pt)
*
|
2002-09-05 |
2021-05-25 |
Bavarian Nordic As |
método para o cultivo de células primárias e para a amplificação de vírus sob condições isentas de soro
|
JP2006512097A
(ja)
*
|
2002-12-23 |
2006-04-13 |
シティ・オブ・ホープ |
癌免疫療法におけるp53を発現する改変・ワクシニア・アンカラ
|
WO2005048957A2
(en)
*
|
2003-02-20 |
2005-06-02 |
Therion Biologics Corporation |
Novel insertion sites in pox vectors
|
US20050175627A1
(en)
*
|
2003-09-24 |
2005-08-11 |
Oxxon Therapeutics Ltd. |
HIV pharmaccines
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
CA2610919C
(en)
|
2005-06-17 |
2013-09-10 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Hepatitis c virus nucleic acid vaccine
|
WO2007136763A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Sanofi Pasteur, Inc. |
Immunological composition
|
US20080010527A1
(en)
*
|
2006-06-26 |
2008-01-10 |
Inventec Corporation |
Method of solving BIST failure of CPU by means of BIOS and maximizing system performance
|
CA2662730A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Bavarian Nordic A/S |
Phenotypic and genotypic differences of mva strains
|
CA2665068C
(en)
|
2006-10-06 |
2016-01-05 |
Bn Immunotherapeutics Inc. |
Methods for treating cancer with mva
|
WO2009100521A1
(en)
|
2008-02-12 |
2009-08-20 |
Sanofi Pasteur Limited |
Methods using ion exchange and gel filtration chromatography for poxvirus purification
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
US7998488B2
(en)
*
|
2008-11-14 |
2011-08-16 |
Baxter International Inc. |
Vaccine formulations and uses thereof
|
WO2010127115A1
(en)
|
2009-04-30 |
2010-11-04 |
Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) |
Modified immunization vectors
|
WO2011087839A1
(en)
|
2009-12-22 |
2011-07-21 |
Baxter International Inc. |
Vaccine to influenza a virus
|
NZ600629A
(en)
|
2010-01-28 |
2014-12-24 |
Bavarian Nordic As |
Vaccinia virus mutants containing the major genomic deletions of mva
|
CN103492410A
(zh)
|
2010-03-12 |
2014-01-01 |
梅里亚有限公司 |
蓝舌病毒重组疫苗和其使用
|
EP2668201A2
(de)
|
2011-01-28 |
2013-12-04 |
Sanofi Pasteur SA |
Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
|
WO2012151272A2
(en)
|
2011-05-02 |
2012-11-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
EP2788021B1
(de)
|
2011-12-09 |
2017-01-18 |
Bavarian Nordic A/S |
Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
|
SI2879702T1
(sl)
|
2012-08-01 |
2020-02-28 |
Bavarian Nordic A/S |
Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
|
WO2014037124A1
(en)
|
2012-09-04 |
2014-03-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
CA2888367A1
(en)
|
2012-10-19 |
2014-04-24 |
Bavarian Nordic, Inc. |
Methods and compositions for the treatment of cancer
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
MY188100A
(en)
|
2013-11-28 |
2021-11-18 |
Bavarian Nordic As |
Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
WO2015175340A1
(en)
|
2014-05-13 |
2015-11-19 |
Bavarian Nordic, Inc. |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
|
ES2777323T3
(es)
|
2014-09-03 |
2020-08-04 |
Bavarian Nordic As |
Procedimientos y composiciones para inducir inmunidad protectora contra infección por filovirus
|
WO2016036971A1
(en)
|
2014-09-03 |
2016-03-10 |
Bavarian Nordic A/S |
Methods and compositions for enhancing immune responses
|
KR101971808B1
(ko)
|
2014-09-26 |
2019-04-23 |
베쓰 이스라엘 디코니스 메디칼 센터 인크 |
인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
|
EP3757211A1
(de)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Verfahren zur profilierung des t-zell-rezeptor-repertoirs
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
PL3271729T3
(pl)
|
2015-03-18 |
2021-05-04 |
Janssen Vaccines & Prevention B.V. |
Oznaczenia systemów ekspresji rekombinowanej
|
IL255769B2
(en)
|
2015-05-20 |
2023-09-01 |
Broad Inst Inc |
shared neoantigens
|
TWI792091B
(zh)
|
2015-12-15 |
2023-02-11 |
荷蘭商傑森疫苗防護公司 |
人類免疫缺陷病毒抗原、載體、組成物、及其使用方法
|
DK3407910T3
(da)
|
2016-01-29 |
2022-07-18 |
Bavarian Nordic As |
Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
CN109219448B
(zh)
|
2016-06-16 |
2022-09-20 |
扬森疫苗与预防公司 |
Hiv疫苗配制品
|
EP3484507A1
(de)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Verfahren und zusammensetzungen zur induzierung von schützender immunität gegen eine marburg-virus-infektion
|
CN110494159A
(zh)
|
2016-09-02 |
2019-11-22 |
扬森疫苗与预防公司 |
在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
|
RS60919B1
(sr)
|
2016-09-15 |
2020-11-30 |
Janssen Vaccines & Prevention Bv |
Trimer koji stabilizuje mutacije proteina omotača hiv
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
ES2965475T3
(es)
|
2017-02-12 |
2024-04-15 |
Biontech Us Inc |
Métodos y composiciones basados en HLA y usos de los mismos
|
WO2018185732A1
(en)
|
2017-04-06 |
2018-10-11 |
Janssen Vaccines & Prevention B.V. |
Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
|
JP7272965B2
(ja)
|
2017-06-15 |
2023-05-12 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hiv抗原をコードするポックスウイルスベクターおよびその使用方法
|
SG11202000112XA
(en)
|
2017-07-19 |
2020-02-27 |
Janssen Vaccines & Prevention Bv |
Trimer stabilizing hiv envelope protein mutations
|
WO2019018724A1
(en)
|
2017-07-21 |
2019-01-24 |
Janssen Vaccines & Prevention B.V. |
METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
|
US20190083620A1
(en)
|
2017-09-18 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
JP7320601B2
(ja)
|
2018-09-11 |
2023-08-03 |
上▲海▼市公共▲衛▼生▲臨▼床中心 |
広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CA3124457A1
(en)
|
2018-12-21 |
2020-06-25 |
Biontech Us Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
CA3161800A1
(en)
|
2019-11-18 |
2021-05-27 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
JP2023521194A
(ja)
|
2020-04-13 |
2023-05-23 |
ヤンセン バイオテツク,インコーポレーテツド |
Psma及びsteap1ワクチン並びにそれらの使用
|
KR20230029673A
(ko)
|
2020-05-26 |
2023-03-03 |
디오니스 테라퓨틱스, 아이엔씨. |
핵산 인공 미니-프로테옴 라이브러리
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
AU2021400424A1
(en)
|
2020-12-14 |
2023-07-06 |
Biontech Us Inc. |
Tissue-specific antigens for cancer immunotherapy
|
WO2023077147A2
(en)
|
2021-11-01 |
2023-05-04 |
Pellis Therapeutics, Inc. |
T-cell vaccines for patients with reduced humoral immunity
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
WO2023220283A1
(en)
|
2022-05-12 |
2023-11-16 |
Pellis Therapeutics, Inc. |
Poxvirus adjuvant for t-cell vaccination
|
WO2024011250A1
(en)
|
2022-07-08 |
2024-01-11 |
Viromissile, Inc. |
Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|